MannKind

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MannKind reports strong Q4 earnings, eyes revenue growth opportunities

MannKind's strong financial performance in Q4 2022, driven by revenue growth and improved margins, positions the company for future success.
While challenges exist in healthcare innovation and regulatory processes, MannKind's focus on internal innovation and revenue diversification presents growth opportunities.
Opportunities in collaborations, inhaled therapeutics, and data-driven healthcare outcomes offer avenues for MannKind's future expansion and profitability.
Maintaining financial stability, driving revenue growth, and exploring new product opportunities are key strategies for MannKind's long-term success.

MannKind reports strong Q1 performance, eyes revenue growth opportunities

MannKind's Q1 2023 earnings call highlighted strong performance in royalty revenue, endocrine business, and liquidity position. Challenges include maintaining growth amidst competition, while opportunities lie in revenue growth and strategic collaborations. Overall, MannKind's positive outlook is supported by its pipeline progress and focus on shareholder value.

MannKind achieves first operating income, eyes international expansion for growth

MannKind's Q2 performance reflects significant financial milestones, with revenue growth, operating income, and strong gross margins showcasing operational efficiency and progress towards profitability.
While facing challenges such as trial costs and regulatory requirements, the company's strategic strengths in product expansion, R&D investments, and international partnerships position it for long-term growth.
Opportunities in strong patient demand, international market expansion, orphan lung areas, and product growth present avenues for revenue diversification and sustained performance.
Overall, MannKind's focus on innovation, financial sustainability, and market expansion sets a positive trajectory for future growth and profitability.

MannKind achieves first profitable quarter with strong revenue growth

MannKind's Q3 marked a profitable quarter with significant revenue growth and operational improvements.
Strengths include revenue diversification, margin enhancements, and promising trial progress.
Challenges lie in stabilizing V-Go revenue, fluctuating earnings, and trial design adjustments.
Opportunities include upcoming milestones, market leverage, and Medicare changes for growth.

MannKind reports record 2023 revenues, eyes growth opportunities in 2024

MannKind had a strong financial performance in 2023, with a focus on debt repayment, clinical trials, and shareholder value in 2024. Innovation in powders and NTM asset, along with strategic positioning and sales force optimization, offer growth potential.

MannKind reports record revenue in Q2 2024 earnings call

MannKind's Q2 2024 performance reflects strong revenue growth and progress on key products.
While facing challenges in IP protection and manufacturing capacity, the company maintains a healthy cash position.
Opportunities lie in upcoming milestones and market expansion, with a focus on enhancing financial performance.

MannKind reports record revenue, shifts focus to growth strategies

MannKind delivered strong financial performance, focusing on growth and innovation in its product portfolio. While transitioning Afrezza's mindset poses challenges, strategic investments and market expansion present promising opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Transcript)

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)

MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 2second Annual Global Investment Conference (Transcript)

MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 22nd Annual Global Investment Conference (Transcript)

WESTLAKE VILLAGE, Calif., Aug.  31, 2020  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKind’s medical affairs, field medical activities, safety, and pediatrics initiatives. Dr. Kaiserman will report directly to Michael Castagna, Chief Executive Officer and will be based in MannKind’s Westlake Village, California headquarters.

Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

MannKind (MNKD) in Focus: Stock Moves 8.7% Higher

WESTLAKE VILLAGE, Calif., Aug.  07, 2020  (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 pm (ET). Interested parties can access a link to the live webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020

MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript

MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates

Conference Call to Begin Today at 5:00 PM ET Conference Call to Begin Today at 5:00 PM ET

MannKind Corporation Reports 2020 Second Quarter Financial Results

WESTLAKE VILLAGE, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 5, 2020.

MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020

BioCryst Pharmaceuticals

Fluent Inc

GrubHub

Liquidia Technologies Inc

Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.

Top Stocks To Short As Consumer Confidence Exceeds Expectations

FuelCell Energy

Intellicheck

Tetraphase Pharmaceuticals

We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology have identified several Top Shorts for you to hedge the market with.

Top Stocks To Short Following Fed's New Restrictions For Big Banks

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)

Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks.
The post MannKind Is Crushing It, but Beware or You’ll Be Crushed appeared first on InvestorPlace.

MannKind Is Crushing It, but Beware or You’ll Be Crushed

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

Implied Volatility Surging for MannKind (MNKD) Stock Options

WESTLAKE VILLAGE, Calif., June  17, 2020  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT).  Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.

MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference

Momentum is still in swing from the biotech's recent presentations.

Why MannKind Shares Are Soaring Again Today

Investors liked the biotech's presentations at a major diabetes conference.

Why MannKind Stock Is Crushing It Today

WESTLAKE VILLAGE, Calif., June  15, 2020  (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.

MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at  American Diabetes Association (ADA) 80th Scientific Sessions

WESTLAKE VILLAGE, Calif., June  13, 2020  (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.

Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM

Agenus

Blink Charging

Gritstone Oncology Inc

Ocugen, Inc.

If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and our deep learning algorithms paired with AI have identified several Top Shorts for today.

Top Stocks To Short As The Nasdaq Breaks Above 10,000

Brickell Biotech Inc

Digital Ally Inc

EyePoint Pharmaceuticals

Heat Biologics

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short today.

Top Stocks To Short As Market Ignores Widespread Protests

MannKind Corporation's (MNKD) CEO Michael Castagna on Q1 2020 Results - Earnings Call Transcript

News for MannKind Stock (MNKD)